REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
21/07/2025
Voltar para busca
Dado oficial do USPTO
CORDEN PHARMA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
CORDEN PHARMA
ST13
US500000079264557Classe
40, 42
Pedido
79264557
Registro
6104161
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
34
Atualização mais recente
22/07/2025
Tipo de marca
Verbal
Classes Nice
40, 42
Data de depósito
11/06/2019
Data de registro
21/07/2020
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
21/07/2020
Última transação
22/07/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
DE
Examinador
BELENKER, ESTHER
Unidade examinadora
M20
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Corden Pharma International GmbH
Corden Pharma Holding S.E.
Representantes
Jeffrey H. Handelsman Greenblum & Bernstein, P.L.C.
Classificação técnica
Classes Nice
Classe 40Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 40
Custom manufacture of pharmaceuticals; treatment of chemical products; recycling of chemical products
Classe 42
Pharmaceutical research services; quality evaluation of pharmaceutical products; development of pharmaceutical products; inspection of pharmaceutical products; research in the field of pharmaceutical products; testing on pharmaceutical products; pharmaceutical product development services; development of pharmaceutical preparations and medicines; laboratory research services concerning pharmaceutical products; research and development for the pharmaceutical industry; consultancy in the field of pharmaceutical research; services for conducting early assessments of new pharmaceuticals; provision of information concerning the results of clinical trials for pharmaceutical products; industrial packaging design services; chemical laboratory services; chemical engineering services; chemical analysis; chemical research; testing of chemical products; chemical technology research; analysis of the chemical composition of liquids; evaluation of chemical information to estimate risk levels
Publicações
Histórico de despachos e eventos da marca no USPTO.
34 publicações encontradas
NREP
NEW REPRESENTATIVE AT IB RECEIVED
19/05/2023
CHLD
CHANGE OF OWNER RECEIVED FROM IB
28/04/2023
FINV
FINAL DECISION TRANSACTION PROCESSED BY IB
05/12/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
13/11/2020
FIMP
FINAL DISPOSITION PROCESSED
12/11/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
21/10/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
21/07/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/05/2020
PUBO
PUBLISHED FOR OPPOSITION
05/05/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
15/04/2020
ALIE
ASSIGNED TO LIE
26/03/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
21/03/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
20/03/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
20/03/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
20/03/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
20/03/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
27/01/2020
GNRT
NON-FINAL ACTION E-MAILED
27/01/2020
CNRT
NON-FINAL ACTION WRITTEN
27/01/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
25/01/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
24/01/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
24/01/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
24/01/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
24/01/2020
RFNT
REFUSAL PROCESSED BY IB
26/10/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/10/2019
RFRR
REFUSAL PROCESSED BY MPU
03/10/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
19/09/2019
CNRT
NON-FINAL ACTION WRITTEN
18/09/2019
DOCK
ASSIGNED TO EXAMINER
01/09/2019
MAFR
APPLICATION FILING RECEIPT MAILED
20/08/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
15/08/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/08/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace CORDEN PHARMA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.